Adaptimmune Therapeutics plc announced the appointment of Joanna (Jo) Brewer as Chief Scientific Officer effective immediately. Most recently Brewer served as Senior Vice President, Allogeneic Research at Adaptimmune since December 2019. In this role, she built the Allogeneic Research organization from the ground up and took the concept of iPSC-derived allogeneic T-cell therapies from an idea into the potential for an allogeneic candidate in the clinic.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -6.54% | -3.85% | +26.10% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.10% | 258M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+1.69% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ADAP Stock
- News Adaptimmune Therapeutics plc
- Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer